Fulgent Genetics Q4 Earnings Assessment
Benzinga Insights 8 months ago
Earnings
The Q4 earnings report for Fulgent Genetics (NASDAQ:FLGT) was released on Friday, February 27, 2026 at 07:00 AM.
Here's what investors need to know about the latest announcement.
Earnings
Fulgent Genetics beat estimated earnings by 277.78%, reporting an EPS of $0.16 versus an estimate of $-0.09.
Revenue was up $7.12 million from the same period last year.
Overview of Past Earnings
The company beat on EPS by $0.5 in the last quarter, resulting in a 18.15% increase share price change the following day.
Here's a look at Fulgent Genetics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.36 | -0.33 | -0.18 | -0.12 |
| EPS Actual | 0.14 | 0.07 | 0.04 | 0.04 |
| Revenue Estimate | 81.36M | 76.08M | 71.26M | 74.79M |
| Revenue Actual | 84.07M | 81.80M | 73.46M | 76.21M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Fulgent Genetics management provided guidance for FY 2026, expecting earnings between $-1.45 and $-1.45 per share.
To track all earnings releases for Fulgent Genetics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.